期刊
CANCER LETTERS
卷 385, 期 -, 页码 261-270出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.10.010
关键词
Amphiregulin; VEGF-A; Angiogenesis; miR-206
类别
资金
- Ministry of Science and Technology of Taiwan [NSC 102-2632-B-039-001-MY3, MOST 103-2628-B-039-002-MY3]
- China Medical University [CMU103-AISA-03]
Chondrosarcoma is the second most common primary malignancy of bone after myeloma and osteosarcoma. Chondrosarcoma development may be linked to angiogenesis, which is principally elicited by vascular endothelial growth factor-A (VEGF-A). The expression of VEGF-A has been recognized as a prognostic marker in angiogenesis. Amphiregulin (AR), an epidermal growth factor receptor ligand, promotes tumor proliferation, metastasis and angiogenesis. However, the role of AR in VEGF-A expression and angiogenesis in human chondrosarcoma remains largely unknown. This current study shows that AR promoted VEGF-A production and induced angiogenesis of human endothelial progenitor cells. Moreover, AR-enhanced VEGF-A expression and angiogenesis involved the FAK, c-Src and PKC delta signaling pathways, while miR-206 expression was negatively mediated by AR via the FAK, c-Src and PKC delta pathways. Our results illustrate the clinical significance between AR, VEGF-A and miR-206, as well as tumor stage, in human chondrosarcoma. AR may represent a novel therapeutic target in the metastasis and angiogenesis of chondrosarcoma. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据